Previous close | 15.54 |
Open | 15.62 |
Bid | 15.53 x 100 |
Ask | 19.98 x 200 |
Day's range | 15.50 - 16.03 |
52-week range | 8.90 - 38.85 |
Volume | |
Avg. volume | 64,582 |
Market cap | 392.282M |
Beta (5Y monthly) | 1.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -25.95 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.00 |
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updat
Cibus ( NASDAQ:CBUS ) Full Year 2023 Results Key Financial Results Net loss: US$267.6m (loss widened by US$250.7m from...
Completed successful transfers of gene edited elite germplasm back to customers for commercialization for each of its three developed productivity traits: Pod Shatter Reduction (PSR) in Canola and Herbicide Tolerance (HT1 and HT3) in Rice Signed collaboration agreements for trait development with multiple major seed companies, including Bayer, Loveland Products (subsidiary of Nutrien Ltd), Nuseed, and Interoc Reported achievement of successful greenhouse results for two different modes of action